Skip to search formSkip to main contentSkip to account menu

efaproxiral

Known as: 2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid, 2-Dacmpp, Efaproxyn 
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (4)

Aniline CompoundsAntisickling AgentsPropionatesRadiation-Sensitizing Agents

Narrower (3)

Efaproxiral SodiumRSR 13RSR 56

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Treatment of brain metastases: review of phase III randomized controlled trials.
Review
2009
Review
2009
Whole brain radiotherapy with radiosensitizer for brain metastases
PurposeTo study the efficacy of whole brain radiotherapy (WBRT) with radiosensitizer in comparison with WBRT alone for patients… 
Highly Cited
2008
Highly Cited
2008
Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral.
A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction… 
Highly Cited
2007
Highly Cited
2007
Improved Survival, Quality of Life, and Quality-Adjusted Survival in Breast Cancer Patients Treated With Efaproxiral (Efaproxyn) Plus Whole-Brain Radiation Therapy for Brain Metastases
Objective:To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality of life and quality of… 
2007
2007
The Effects of Efaproxyn™ (Efaproxiral) on Subcutaneous RIF-1 Tumor Oxygenation and Enhancement of Radiotherapy-Mediated Inhibition of Tumor Growth in Mice
Abstract Hou, H., Khan, N., Grinberg, O. Y., Yu, H., Grinberg, S. A., Lu, S., Demidenko, E., Steffen, R. P. and Swartz, H. M. The… 
Highly Cited
2006
Highly Cited
2006
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
  • J. Suh, B. Stea, E. Shaw
  • Journal of clinical oncology : official journal…
  • 2006
  • Corpus ID: 21005938
PURPOSE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain… 
Review
2006
Review
2006
Current therapeutic approaches in patients with brain metastases
Opinion statementThe development of brain metastases is often viewed as the end stage of a disease course and engenders… 
2005
2005
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
PURPOSE Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We… 
2004
2004
Efaproxiral: a novel radiation sensitiser
  • J. Suh
  • Expert opinion on investigational drugs
  • 2004
  • Corpus ID: 22624281
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. By facilitating… 
Highly Cited
2002
Highly Cited
2002
Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy…
PURPOSE The objectives of this phase II study were to determine survival, safety, pharmacokinetics (PK), and pharmacodynamics (PD… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)